Global Retirement Partners LLC Raises Stock Holdings in Amgen Inc. $AMGN

Global Retirement Partners LLC raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 34.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,071 shares of the medical research company’s stock after acquiring an additional 5,691 shares during the period. Global Retirement Partners LLC’s holdings in Amgen were worth $7,224,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in Amgen by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after buying an additional 961,975 shares during the period. Capital International Investors raised its holdings in Amgen by 1.5% during the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock valued at $5,414,296,000 after buying an additional 282,219 shares during the period. Capital World Investors raised its holdings in Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after buying an additional 1,935,876 shares during the period. Capital Research Global Investors raised its holdings in Amgen by 2.7% during the 3rd quarter. Capital Research Global Investors now owns 4,731,290 shares of the medical research company’s stock valued at $1,335,168,000 after buying an additional 122,631 shares during the period. Finally, Invesco Ltd. raised its holdings in Amgen by 6.6% during the 3rd quarter. Invesco Ltd. now owns 4,467,287 shares of the medical research company’s stock valued at $1,260,668,000 after buying an additional 277,031 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.85% of the stock is owned by company insiders.

Amgen Stock Performance

Shares of Amgen stock opened at $337.42 on Friday. The stock’s fifty day moving average is $345.86 and its two-hundred day moving average is $344.41. The company has a market capitalization of $182.10 billion, a PE ratio of 23.48, a price-to-earnings-growth ratio of 3.33 and a beta of 0.44. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts expect that Amgen Inc. will post 22.37 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is 70.15%.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s xaluritamig prostate cancer trial is advancing, which supports the company’s long-term pipeline narrative and could improve investor confidence in future oncology revenue. Amgen Advances Xaluritamig Trial in Hard-to-Treat Prostate Cancer
• Positive Sentiment: Analysts remain constructive on Amgen despite a small target cut, with Piper Sandler reiterating an Overweight rating and other coverage pointing to pipeline strength and sales growth. Amgen Inc. (AMGN): Navellier’s Long-Term Pick on Pipeline Strength and Sales Growth
• Positive Sentiment: Argus lowered its price target to $375 from $400 but kept a Buy rating, reinforcing the view that Amgen still has upside from current levels. Argus adjusts price target on Amgen to $375 from $400, maintains Buy rating
• Neutral Sentiment: Amgen was included in a broad report on the late-stage chronic kidney disease market, which is more of an industry overview than a company-specific catalyst. Late-Stage Chronic Kidney Disease Market Analysis Report 2026-2036
• Negative Sentiment: Amgen’s rare-disease drug Tavneos faced new warning-related scrutiny in Japan after patient deaths, though regulators later allowed new patients to be prescribed the drug again; this may still weigh on sentiment because it highlights safety risk. Doctors in Japan can again prescribe an Amgen rare-disease drug to new patients, reversing a recommendation made only days ago following 20 deaths
• Negative Sentiment: A broader Senate bill on maternal health could affect large pharma and biotech companies indirectly through future research, surveillance, and policy changes, but it is not an immediate Amgen-specific driver. New Bill: Senator Elizabeth Warren introduces S. 4550: Maternal Health Pandemic Response Act

Analysts Set New Price Targets

Several research firms recently weighed in on AMGN. Argus decreased their price target on Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a report on Wednesday. Barclays began coverage on Amgen in a report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price target on the stock. Jefferies Financial Group began coverage on Amgen in a report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price target on the stock. Canaccord Genuity Group began coverage on Amgen in a report on Monday, April 20th. They set a “hold” rating and a $366.00 price target on the stock. Finally, Rothschild & Co Redburn increased their price target on Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a report on Wednesday, February 18th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Amgen currently has a consensus rating of “Hold” and an average target price of $355.19.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.